What is Mallinckrodt Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Mallinckrodt's interest expense for the
three
months ended in Mar. 2024 was $ -59 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-355 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Mallinckrodt's Operating Income for the
three
months ended in Mar. 2024 was $ -8 Mil. Mallinckrodt's Interest Expense for the
three
months ended in Mar. 2024 was $ -59 Mil.
Mallinckrodt did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Mallinckrodt Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-355 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mallinckrodt (OTCPK:MCKPF) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Mallinckrodt's Interest Expense for the
three
months ended in Mar. 2024 was $-59 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-8 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $1,748 Mil.
Mallinckrodt's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Mallinckrodt did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Mallinckrodt (Mallinckrodt) Business Description
Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
| Alta Fundamental Advisers Llc |
10 percent owner |
1500 BROADWAY, SUITE 704, NEW YORK NY 10036 |
| Jason Daniel Goodson |
officer: EVP & Head of Corp Development |
106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885 |
| James R Sulat |
director |
|
| Paul Bisaro |
director |
|
| Sigurdur O Olafsson |
director, officer: President and CEO |
360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960 |
| Stephen Andrew Welch |
officer: EVP & Head of Spec Generics |
18440 BRIDGEMORE LANE, LOUISVILLE KY 40245 |
| Peter C Richardson |
officer: EVP & Chief Scientific Officer |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
| Susan Michele Silbermann |
director |
C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540 |
| Lisa French |
officer: EVP & Chief Commercial Officer |
301 CONTINENTAL LANE, PAOLI PA 19301 |
| Mark Anthony Tyndall |
officer: EVP & Chief Legal Offi & Secre |
1101 Q ST NW, WASHINGTON DC 20009 |
| Henriette Nielsen |
officer: EVP & Chief Transformation OFC |
202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024 |
| Karen Ling |
director |
C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
| Anne Clem Whitaker |
director |
109 BRIERY BRANCH COURT, MORRISVILLE NC 27560 |
| Olifant Luxco S.a R.l. |
10 percent owner |
19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273 |
| Paul Rutherford Carter |
director |
SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF |
Mallinckrodt (Mallinckrodt) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCKPF has been successfully added to your 